Imbruvica Description

Capsules: Each 140 mg capsule is a size 0, white opaque, hard gelatin capsule with black printing 'ibr 140 mg', containing off-white to white powder.
Tablets: Each 140 mg tablet is a yellow-green to green round tablet debossed on one side with "ibr" and "140" on the other side.
Ibrutinib is kinase inhibitor. It is a white to off-white solid with the empirical formula C₂₅H₂₄N₆O₂ and a molecular weight 440.50. Ibrutinib is freely soluble in dimethyl sulfoxide, soluble in methanol and practically insoluble in water.
The chemical name for ibrutinib is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one.
IMBRUVICA (ibrutinib) is available as immediate-release oral capsules and immediate-release oral tablets.
IMBRUVICA (ibrutinib) capsules for oral use is available in the following dosage strength: 140 mg.
IMBRUVICA (ibrutinib) tablets for oral use is available in the following dosage strength: 140 mg.
Excipients/Inactive Ingredients: Each capsule contains the following inactive ingredients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate. The capsule shell contains gelatin, titanium dioxide, and black ink.
Each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl sulfate. The film coating for each tablet contains ferrosoferric oxide, polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and yellow iron oxide.